Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts

Translational Oncology

Volumn 6, Issue 4, 2013, Pages 493-503

  Kumar, Sushil ^a,b   Mokhtari, Reza Bayat ^a,b   Oliveira, Indhira Dias ^c   Islam, Syed ^a   Toledo, Silvia Regina Caminada ^c   Yeger, Herman ^a,b   Baruchel, Sylvain ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER; PAZOPANIB; TOPOTECAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; METRONOMIC DRUG ADMINISTRATION; MITOSIS RATE; MOUSE; NEUROBLASTOMA; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84881082484     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13286     Document Type: Article

References (63)

1. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, Smith FO, and Reaman GH (2010). Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28, 2625-2634.
2. SEER (2003). Surveillance, epidemiology, and end results (SEER) program web site. Available at http://www.seer.cancer.gov.
3. Taylor M, Rössler J, Geoerger B, Vassal G, and Farace F (2010). New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future. Expert Opin Investig Drugs 19, 859-874.
4. Kerbel RS and Kamen BA (2004). The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4, 423-436.
5. Stempak D, Seely D, and Baruchel S (2006). Metronomic dosing of chemotherapy: applications in pediatric oncology. Cancer Invest 24, 432-443.
6. Hackl C, Man S, Francia G, Milsom C, Xu P, and Kerbel RS (2013). Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved pre-clinical orthotopic and adjuvant therapy colon cancer models. Gut 62, 259-271.
7. Pasquier E, Kavallaris M, and André N (2010). Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7, 455-465.
8. Wei J, DeAngulo G, Sun W, Hussain SF, Vasquez H, Jordan J, Weinberg J, Wolff J, Koshkina N, and Heimberger AB (2009). Topotecan enhances immune clearance of gliomas. Cancer Immunol Immunother 58, 259-270.
9. Galluzzi L, Senovilla L, Zitvogel L, and Kroemer G (2012). The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 3, 215-233.
10. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, and Kerbel RS (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105, R15-R24.
11. Hartwich J, Orr WS, Ng CY, Spence Y, Morton C, and Davidoff AM (2013). HIF-1α activation mediates resistance to anti-angiogenic therapy in neuro-blastoma xenografts. J Pediatr Surg 48, 39-46.
12. Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, Kim G, Fruehauf J, Imagawa DK, Hoffman RM, and Katz MH (2010). Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther 9, 2068-2078.
13. Jia L and Waxman DJ (2013). Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis. Cancer Lett 330, 241-249.
14. Wang R, Qin S, Chen Y, Li Y, Chen C, Wang Z, Zheng R, and Wu Q (2012). Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer. Oncol Rep 28, 439-445.
15. Eichbaum M, Mayer C, Eickhoff R, Bischofs E, Gebauer G, Fehm T, Lenz F, Fricke HC, Solomayer E, Fersis N, et al. (2011). The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer 20, 453.
16. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, et al. (2008). Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26, 4899-4905.
17. Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G, Viale G, Veronesi P, Luini A, Intra M, et al. (2012). Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer 12, 207-214.
18. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, et al. (2008). Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26, 76-82.
19. Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, and Baruchel S (2006). A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 28, 720-728.
20. Felgenhauer JL, Nieder ML, Krailo MD, Bernstein ML, Henry DW, Malkin D, Baruchel S, Chuba PJ, Sailer SL, Brown K, et al. (2013). A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multi-agent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: a Children's Oncology Group (COG) phase II study NCT00061893. Pediatr Blood Cancer 60, 409-414.
21. Pasquier E, Kieran MW, Sterba J, Shaked Y, Baruchel S, Oberlin O, Kivivuori MS, Peyrl A, Diawarra M, Casanova M, et al. (2011). Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Transl Oncol 4, 203-211.
22. Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, and Kerbel RS (2010). Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 9, 996-1006.
23. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, et al. (2010). Bridging the gap between cyto-toxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 9, 985-995.
24. Kumar S, Mokhtari RB, Sheikh R, Wu B, Zhang L, Xu P, Man S, Oliveira ID, Yeger H, Kerbel RS, et al. (2011). Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res 17, 5656-5667.
25. Tillmanns TD, Reed ME, Privett MC, Johns AL, Walker MS, and Houts AC (2012). Phase I trial of metronomic oral topotecan in combination with pazo-panib utilizing a daily dosing schedule to treat recurrent or persistent gynecologic tumors. In Proceedings of American Society for Clinical Oncology Annual Meeting (ASCO), Chicago, IL. Abstract #5014.
26. Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, et al. (2007). Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 9, 354-363.
27. Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, Leenders WP, and van Furth WR (2009). Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9, 444.
28. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE II, Marcello JE, Norfleet J, et al. (2009). Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101, 1986-1994.
29. Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE II, Marcello J, Threatt S, et al. (2011). Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 103, 371-379.
30. Tamaskar I, Dhillon J, and Pili R (2011). Resistance to angiogenesis inhibitors in renal cell carcinoma. Clin Adv Hematol Oncol 9, 101-110.
31. Sorensen BS, Hao J, Overgaard J, Alsner J, and Horsman MR (2005). Validating the use of CAIX and GLUT1 as endogenous markers for hypoxia in solid tumors. In Proceedings of 96th Annual Meeting of the American Association for Cancer Research (AACR), Anaheim, CA. Abstract #1130.
32. Milane L, Duan Z, and Amiji M (2011). Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int 11, 3.
33. Bergers G and Hanahan D (2008). Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8, 592-603.
34. Loges S, Schmidt T, and Carmeliet P (2010). Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 1, 12-25.
35. Yu JL, Rak JW, Coomber BL, Hicklin DJ, and Kerbel RS (2002). Effect of p53 status on tumor response to antiangiogenic therapy. Science 295, 1526-1528.
36. Thoenes L, Hoehn M, Kashirin R, Ogris M, Arnold GJ, Wagner E, and Guenther M (2010). In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy. J Proteomics 73, 1342-1354.
37. Kubisch R, Meissner L, Krebs S, Blum H, Günther M, Roidl A, and Wagner E (2013). A comprehensive gene expression analysis of resistance formation upon metronomic cyclophosphamide therapy. Transl Oncol 6, 1-9.
38. Pasquier E, Tuset MP, Street J, Sinnappan S, Mackenzie KL, Braguer D, Andre N, and Kavallaris M (2013). Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells. Angiogenesis 16, 373-386.
39. Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, Redrado M, Bleau AM, Prior C, Bertolini F, and Calvo A (2012). Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest 92, 952-966.
40. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, and Kerbel RS (2011). Tumors that acquire resistance to low-dose metronomic cyclo-phosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13, 40-48.
41. Veas-Perez Tudela M, Delgado-Esteban M, Cuende J, Bolanos JP, and Almeida A (2010). Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase. J Neurochem 113, 819-825.
42. Rapisarda A and Melillo G (2012). Overcoming disappointing results with anti-angiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 9, 378-390.
43. Puppo M, Battaglia F, Ottaviano C, Delfino S, Ribatti D, Varesio L, and Bosco MC (2008). Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuro-blastoma by targeting hypoxia-inducible factor-1α and -2α. Mol Cancer Ther 7, 1974-1984.
44. Beppu K, Nakamura K, Linehan WM, Rapisarda A, and Thiele CJ (2005). Topotecan blocks hypoxia-inducible factor-1α and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res 65, 4775-4781.
45. di Tomaso E, London N, Fuja D, Logie J, Tyrrell JA, Kamoun W, Munn LL, and Jain RK (2009). PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS One 4, e5123.
46. Abramsson A, Lindblom P, and Betsholtz C (2003). Endothelial and non-endothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112, 1142-1151.
47. Liu CY, Chang HS, Chen IS, Chen CJ, Hsu ML, Fu SL, and Chen YJ (2011). Costunolide causes mitotic arrest and enhances radiosensitivity in human hepatocellular carcinoma cells. Radiat Oncol 6, 56.
48. Lee CC, Lin YH, Chang WH, Lin PC, Wu YC, and Chang JG (2011). Squamocin modulates histone H3 phosphorylation levels and induces G1 phase arrest and apoptosis in cancer cells. BMC Cancer 11, 58.
49. Box AH and Demetrick DJ (2004). Cell cycle kinase inhibitor expression and hypoxia-induced cell cycle arrest in human cancer cell lines. Carcinogenesis 25, 2325-2335.
50. Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV, and Joshi KS (2012). Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells. Prostate Cancer Prostatic Dis 15, 15-27.
51. Lou J, Zhou X, Weng Q, Wang DD, Xia Q, Hu Y, He Q, Yang B, and Luo P (2010). XQ2, a novel TPZ derivative, induced G2/M phase arrest and apoptosis under hypoxia in non-small cell lung cancer cells. Biosci Biotechnol Biochem 74, 1181-1187.
52. Feeney GP, Errington RJ, Wiltshire M, Marquez N, Chappell SC, and Smith PJ (2003). Tracking the cell cycle origins for escape from topotecan action by breast cancer cells. Br J Cancer 88, 1310-1317.
53. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I, and West C (2001). Glucose transporter Glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7, 928-934.
54. Vander Heiden MG, Cantley LC, and Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033.
55. Qing G, Skuli N, Mayes PA, Pawel B, Martinez D, Maris JM, and Simon MC (2010). Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1α. Cancer Res 70, 10351-10361.
56. Matsushita K, Uchida K, Saigusa S, Ide S, Hashimoto K, Koike Y, Otake K, Inoue M, Tanaka K, and Kusunoki M (2012). Glycolysis inhibitors as a potential therapeutic option to treat aggressive neuroblastoma expressing GLUT1. J Pediatr Surg 47, 1323-1330.
57. Kang SS, Chun YK, Hur MH, Lee HK, Kim YJ, Hong SR, Lee JH, Lee SG, and Park YK (2002). Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res 93, 1123-1128.
58. Chung FY, Huang MY, Yeh CS, Chang HJ, Cheng TL, Yen LC, Wang JY, and Lin SR (2009). GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer 9, 241.
59. Rademakers SE, Lok J, van der Kogel AJ, Bussink J, and Kaanders JH (2011). Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 11, 167.
60. Mathupala SP, Ko YH, and Pedersen PL (2006). Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25, 4777-4786.
61. Gershon RT, Crowther AJ, Tikunov A, Garcia I, Annis R, Yuan H, Miller CR, Macdonald J, Olson J, and Deshmukh M (2013). Hexokinase-2-mediated aerobic glycolysis is integral to cerebellar neurogenesis and pathogenesis of medulloblastoma. Cancer Metab 1, 2.
62. Shulga N, Wilson-Smith R, and Pastorino JG (2009). Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism. Cell Cycle 8, 3355-3364.
63. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, and Sorensen AG (2009). Biomarkers of response and resistance to anti-angiogenic therapy. Nat Rev Clin Oncol 6, 327-338.